Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations

被引：91
|
作者：
Ahn, Inhye E. [1 ]
Tian, Xin [1 ]
Wiestner, Adrian [1 ]
机构：
[1] NHLBI, Bldg 10, Bethesda, MD 20892 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 05期
关键词：
CLL;
D O I：
10.1056/NEJMc2005943
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with chronic lymphocytic leukemia with chromosome 17 abnormalities have a worse prognosis than those without such alterations. In this phase 2 study, patients who received continuous ibrutinib had a durable response that continued after 6.5 years in some patients.
引用
收藏
页码：498 / 500
页数：3
相关论文
共 50 条
  • [1] TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?
    Bomben, Riccardo
    Zucchetto, Antonella
    Gentile, Massimo
    Gattei, Valter
    CLINICAL CANCER RESEARCH, 2021, 27 (16) : 4462 - 4464
  • [2] Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
    Cafforio, Luciana
    Raponi, Sara
    Cappelli, Luca Vincenzo
    Ilari, Caterina
    Soscia, Roberta
    De Propris, Maria Stefania
    Mariglia, Paola
    Rigolin, Gian Matteo
    Bardi, Antonella
    Peragine, Nadia
    Piciocchi, Alfonso
    Arena, Valentina
    Mauro, Francesca Romana
    Cuneo, Antonio
    Guarini, Anna
    Foa, Robin
    Del Giudice, Ilaria
    HAEMATOLOGICA, 2022, 107 (01) : 334 - 337
  • [3] TP53 Aberrations in Chronic Lymphocytic Leukemia
    Trbusek, Martin
    Malcikova, Jitka
    ADVANCES IN CHRONIC LYMPHOCYTIC LEUKEMIA, 2013, 792 : 109 - 131
  • [4] Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis
    Liu, Yen-Chun
    Margolskee, Elizabeth
    Allan, John N.
    Mathew, Susan
    Bhavsar, Erica
    Casano, Joseph
    Orazi, Attilio
    Furman, Richard R.
    Geyer, Julia T.
    MODERN PATHOLOGY, 2020, 33 (03) : 344 - 353
  • [5] IBRUTINIB TREATMENT DOESN'T INDUCE TP53 CLONAL EVOLUTION IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Cafforio, L.
    Cappelli, L. V.
    Del Giudice, I.
    Ilari, C.
    Raponi, S.
    De Propris, M. S.
    Mariglia, P.
    Piciocchi, A.
    Arena, V.
    Vignetti, M.
    Mauro, F. R.
    Guarini, A.
    Foa, R.
    HAEMATOLOGICA, 2019, 104 : 1 - 2
  • [6] TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IMMUNOCHEMOTHERAPY AND IBRUTINIB
    Cafforio, L.
    Cappelli, L. V.
    Del Giudice, I.
    Ilari, C.
    Raponi, S.
    Mariglia, P.
    De Propris, M. S.
    Filetti, M.
    Mauro, F. R.
    Foa, R.
    Guarini, A.
    HAEMATOLOGICA, 2018, 103 : S27 - S27
  • [7] TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment
    Del Giudice, Ilaria
    Cafforio, Luciana
    Cappelli, Luca Vincenzo
    Ilari, Caterina
    Raponi, Sara
    De Propris, Maria Stefania
    Mariglia, Paola
    Mauro, Francesca Romana
    Vignetti, Marco
    Guarini, Anna
    Foa, Robin
    BLOOD, 2018, 132
  • [8] TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
    Zenz, Thorsten
    Eichhorst, Barbara
    Busch, Raymonde
    Denzel, Tina
    Haebe, Sonja
    Winkler, Dirk
    Buehler, Andreas
    Edelmann, Jennifer
    Bergmann, Manuela
    Hopfinger, Georg
    Hensel, Manfred
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : 4473 - 4479
  • [9] Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib
    Brieghel, Christian
    Aarup, Kathrine
    Torp, Mathias H.
    Andersen, Michael A.
    Yde, Christina W.
    Tian, Xin
    Wiestner, Adrian
    Ahn, Inhye E.
    Niemann, Carsten U.
    CLINICAL CANCER RESEARCH, 2021, 27 (16) : 4531 - 4538
  • [10] IBRUTINIB IS ACTIVE IN TP53-ABERRANT CHRONIC LYMPHOCYTIC LEUKEMIA
    不详
    CANCER DISCOVERY, 2015, 5 (02) : 108 - 108
12345